GSA Capital Partners’s PMV Pharmaceuticals PMVP Stock Holding History

GSA Capital Partners’s Portfolio PMVP Stock Details PMVP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$19K	Buy	+15,441	New	+$19.6K	﹤0.01%	1642
2024 Q4	–	Sell	-73,352	Closed	-$109K	–	1932
2024 Q3	$109K	Sell	73,352 -4,391	-6%	-$6.78K	0.01%	1479
2024 Q2	$126K	Buy	77,743 +38,106	+96%	+$68.7K	0.01%	1510
2024 Q1	$67K	Buy	+39,637	New	+$74K	0.01%	1519
2023 Q4	–	Sell	-13,045	Closed	-$80K	–	1826
2023 Q3	$80K	Sell	13,045 -101,559	-89%	-$698K	0.01%	1398
2023 Q2	$717K	Buy	+114,604	New	+$601K	0.07%	514

Other funds holding PMVP

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

GSA Capital Partners's PMVP Position: Q1 2026 in Review

GSA Capital Partners opened a new position in PMV Pharmaceuticals (PMVP) in Q1 2026: 15,441 shares worth $19K. The stake represents ﹤0.01% of the portfolio and ranks #1642 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in PMVP as recently as Q3 2024.

GSA Capital Partners first reported a position in PMVP in Q2 2023 and has held it in 6 quarters since. The position peaked at $717K in Q2 2023. 69 funds tracked by Wall St. Rank hold PMVP as of Q1 2026.

GSA Capital Partners held 15,441 shares of PMV Pharmaceuticals worth $19K as of Q1 2026.
PMV Pharmaceuticals was a new GSA Capital Partners position in Q1 2026.
PMV Pharmaceuticals made up ﹤0.01% of GSA Capital Partners's portfolio in Q1 2026, its #1642 holding.
GSA Capital Partners first reported a position in PMV Pharmaceuticals in Q2 2023 and has held it in 6 quarters since.
GSA Capital Partners's PMV Pharmaceuticals position peaked at $717K in Q2 2023.
69 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.